Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBITDA Margin (2016 - 2025)

CytomX Therapeutics' EBITDA Margin history spans 12 years, with the latest figure at 1382.5% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 143202.0% year-over-year to 1382.5%; the TTM value through Dec 2025 reached 0.07%, down 2296.0%, while the annual FY2025 figure was 4.72%, 2775.0% down from the prior year.
  • EBITDA Margin reached 1382.5% in Q4 2025 per CTMX's latest filing, down from 237.43% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 49.52% in Q4 2024 to a low of 1382.5% in Q4 2025.
  • Average EBITDA Margin over 5 years is 181.7%, with a median of 32.8% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: skyrocketed 34724bps in 2023, then crashed -143202bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 315.46% in 2021, then surged by 87bps to 39.61% in 2022, then surged by 109bps to 3.74% in 2023, then skyrocketed by 1224bps to 49.52% in 2024, then plummeted by -2892bps to 1382.5% in 2025.
  • Per Business Quant, the three most recent readings for CTMX's EBITDA Margin are 1382.5% (Q4 2025), 237.43% (Q3 2025), and 0.64% (Q2 2025).